Haussen "Amedini" new adaptive disorder initiated Phase III clinical use in NSCLC perioperative treatment.

On September 15, the Insight database showed that Howson's "Amethystini Tablets" launched a Phase III clinical phase III, with a combination of chemotherapy for methadone for non-small cell lung cancer peri-surgical treatment.
The main purpose of this clinical trial is to compare the event-free survival of Amethystini combined chemotherapy or placebo combination chemotherapy as a fully removable EGFR sensitive mutation II-IIIB (Selective IIIA/B) NSCLC perioperative treatment;
of the study was Professor Wu Yilong of Guangdong Provincial People's Hospital, who planned to join 350 patients in the domestic population.
Amele ® is the first three-generation EGFR-TKI innovative drug developed by Haussen Pharmaceuticals and approved by NMPA on March 17, 2020 for "past mesothyl growth factors" The treatment of the subject (EGFR) tyrosine kinase inhibitor (TKI), and the treatment of adult patients with local late stage or metastasis non-small cell lung cancer (NSCLC) who are positive for the T790M mutation, is also the second third generation EGFR-TKI in the world.
is also expected to be the first domestic three-generation EGFR-TKI innovative drug, Amedini will participate in this year's health care negotiations.
In order to prepare for this health care negotiations, Howson has previously taken the initiative to Amethini (55mg x 20 pieces / box) hanging net limit price from 19600 yuan / box to 9800 yuan / box, can be seen Howson this sprint health care catalog firm.
In addition, insight database shows that Howson is currently conducting a number of clinical studies on amethinib, involving non-small cell lung cancer with indications of liver functional impairment, new dosage form suspension, etc., but most of them are in early clinical stage.
In second-line therapy, Amedini's opponent is Ogini, but clinical data show that the two are similar in objective remission rate (ORR) and disease control rate (DCR);
Overall, as the first domestic three-generation EGFR-TKI innovative drug, to the vast number of patients to bring new drug options;
.